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SUMMARY 
Background: The aims were to assess 1) the relationship of asthma control assessed by combining 
epidemiological survey questions and lung function to Health-Related Quality of Life (HRQL) and 2) whether 
individuals with controlled asthma reach similar generic HRQL levels as individuals without asthma.  
Methods: The analysis included 584 individuals without asthma and 498 with asthma who participated in the 
follow-up of the Epidemiological study on Genetics and Environment of Asthma (EGEA). Asthma control was 
assessed from survey questions and lung function, closely adapted from the 2006-2009 Global Initiative for 
Asthma guidelines. The Asthma Quality of Life Questionnaire (AQLQ, scores range:1-7) and the generic SF-36 
(scores range:0-100) were used.  
Results: Adjusted mean total AQLQ score decreased by 0.5 points for each asthma control steps (6.4, 5.9 and 
5.4 for controlled, partly-controlled and uncontrolled asthma respectively, p<0.0001). The differences in SF-36 
scores between individuals with controlled asthma and those without asthma were minor and not significant for 
the PCS (-1, p=0.09), borderline significant for the MCS (-1.6, p=0.05) and small for the 8 domains (<5.1) 
although statistically significant for 4 domains.  
Conclusion: These results support the discriminative properties of the proposed asthma control grading system 
and its use in epidemiology.  
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INTRODUCTION 
Asthma control reflects the disease activity over a short period of time and incorporates exacerbations and 
current clinical control1. Asthma control is important in clinical practice to evaluate patients and their response to 
treatment (the Global Initiative for Asthma-GINA, the National Asthma Education and Prevention Program-
NAEPP) as well as for public health and research. Studies on asthma control have mainly been conducted in 
clinical studies and few epidemiologic studies in large populations of asthmatics have addressed uncontrolled 
asthma assessed in a comprehensive manner by incorporating several dimensions of the disease 2, 3.   
Poor asthma control is associated with generic and specific health-related quality of life (HRQL) indices 4-6. 
Recent articles support the construct validity of the GINA asthma control classification by studying its 
relationship with specific control questionnaires in clinical populations 7, 8. To our knowledge, no study has 
attempted to examine the HRQL impact of asthma control assessed in a comprehensive way following the GINA 
guidelines by combining subjective measures of asthma control through epidemiological survey questions (to 
assess daytime and nighttime symptoms level, rescue medication use and asthma exacerbation) and objective 
measures of asthma control (lung function). Asthma is associated with a decreased quality of life 9, 10, but it is 
unknown whether individuals with controlled asthma have a decreased HRQL compared to those without 
asthma. Such discriminative properties analysis, using a mixed traditional and clinical epidemiological approach, 
including healthy subjects and well characterized asthmatics, 11 would provide construct validity evidence of 
such a grading system of asthma control applicable in epidemiology 12.  
In the frame of the Epidemiological study on the Genetics and Environment of Asthma, bronchial 
hyperresponsiveness and atopy (EGEA), a French case-control and family study on asthma with detailed 
information for asthma control and quality of life for 1082 subjects, the specific hypotheses tested in this article 
are that 1) asthma control, assessed by combining data collected in that epidemiological survey closely adapted 
from the GINA guidelines, has an important impact on the quality of life among individuals with asthma; 2) the 
quality of life achieved in individuals with controlled asthma is similar to the quality of life of individuals 
without asthma.	  
METHODS  
Population 
EGEA is a cohort study (12 years follow-up) based on an initial group of patients with asthma recruited in chest 
clinics (probands, n=388) and their first-degree relatives (n=1244), and a group of population-based subjects 
(n=415). 13-15 Careful attention was given to address potential biases at inclusion and during examination. 15 The 
population of this cross sectional analysis included 1082 individuals (250 probands, 620 relatives of probands  
and 212  population-based subjects) who took part in EGEA2 (2003-2007), with data available for asthma, 
asthma control classification and HRQL (584 without asthma and 498 with current asthma) (Figure 1) 3. Written 
consent was obtained from all participants at both surveys. Ethical approval to carry out the study was obtained 
for both surveys from the relevant committees (Cochin Port-Royal Hospital, Paris for EGEA1 and Necker-
Enfants Malades Hospital, Paris for EGEA2). 
Phenotypes 
Current asthma was defined by a positive answer to one of the two standardized questions: “Have you ever had 
attacks of breathlessness at rest with wheezing?”, “Have you ever had asthma attacks?”, and at least to one 
question about asthma attack, respiratory symptoms (wheezing, nocturnal chest tightness, attack of shortness of 
breath following strenuous activity, at rest or at night) or treatment for asthma in the last 12 months 3. Individuals 
without asthma were defined by negative answers to the first two questions and report of no treatment for asthma 
or respiratory problems in the past 12 months. 
Asthma control was assessed by combining epidemiological data following as much as possible  the 2006-2009 
GINA  (Global Initiative for Asthma) guidelines 16. This classification has already been used in a previous 
publication assessing the determinants of asthma control 3. Asthma was defined as 1) controlled if all the 
following features, assessed on average over the past 3 months except for FEV1,  were present: trouble with 
breathing less than once a week, no asthma attacks, no nocturnal symptoms, short-acting ß2-agonists use twice 
or less per week in the last 3 months, no use of oral steroids in the last 12 months, FEV1 ≥ 80% of predicted 
value, 2) partly controlled if 1 or 2 of the above features were absent, 3) uncontrolled if ≥3 of these features were 
absent or if respiratory problems had caused hospital/emergency department admissions in the last 12 months, or 
if oral steroids had been used in the last 12 months or ≥12 asthma attacks in the past 3 months.  
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Quality of life questionnaires 
Two standardized quality of life questionnaires were used:  
1) The Asthma Quality of Life Questionnaire (AQLQ) 17 an asthma-specific instrument that consists of 
32 questions, relating to the past 2 weeks and  covering four domains: “symptoms”, “activity limitation”, 
“emotional function” and susceptibility to “environmental exposure”. The minimal clinically important 
difference (MCID), which is the smallest difference that has been considered as clinically and socially relevant 
by the developers, is 0.5 18. As previously used in the literature 19, the HRQL score differences have been 
compared to the MCID when addressing the magnitude of the differences observed between groups, although the 
MCID was not initially developed to be used in this context.  
2) The SF-36 (Medical Outcomes Survey 36 item Short Form health survey), a generic questionnaire 
composed of 36 items that covers eight health status domains: physical functioning, role limitations due to 
physical problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional 
problems and mental health 20. The computed scores for each domain and the two summary component scores 
(Physical Component Summary, PCS and Mental Component Summary, MCS) range from 0 to 100, with larger 
scores indicating better health status21.  There are no recommended MCID for the summary scores, but MCIDs 
for the 8 domains have been described in an asthma population (between 10.0 and 16.7) 22. 
Statistical analyses 
Mixed models that take into account the dependence of the subjects within families were conducted with a robust 
estimate of the standard errors (SE) because of the non-normality of the HRQL scores. The assessment of 
comorbidity is important in HRQL research 23. Since co-morbid conditions affect considerably less disease-
specific than generic HRQL measures 24, the analysis using the SF-36 questionnaire were performed among 
individuals without co-morbidity (584 without asthma and 393 with asthma) whereas the analysis using the 
AQLQ were conducted on all individuals with asthma, with a further adjustment on co-morbidity (n=480). The 
analysis was further conducted separately in ICS users (ICS+) and non-ICS users (ICS-) over the past 12 months 
to account for disease severity 2. All analyses were performed using the SAS 9.1 statistical software (SAS 
institute, Cary, NC). 
 
RESULTS 
Subject characteristics 
The frequency of the allergy-related phenotypes (sensitization to aero-allergens, high level of total IgE and 
rhinitis) and bronchial hyperresponsiveness were much higher in individuals with asthma (n=498, mean age 39.4 
years) than in individuals without asthma (n=584, mean age 43.8 years) (table 1). 93% of individuals with 
asthma, reported to have ever had doctor diagnosed asthma and half of them had used ICS in the past 12 months. 
In this population, 44.4%, 29.7% and 25.9% had controlled, partly-controlled and uncontrolled asthma.   
Disease-specific and generic quality of life and asthma control  
Uncontrolled asthma was associated with a significantly decreased total AQLQ score (p<0.0001)  and partly-
controlled asthma showed intermediate total AQLQ scores between controlled and uncontrolled asthma. A 
decrease by at least 0.5 point was observed for all domains and the total AQLQ score when comparing 
uncontrolled asthma to controlled asthma, but was only observed for the symptom score and the total AQLQ 
score when comparing partly-controlled asthma to controlled asthma (Table 2). The AQLQ scores were higher in 
ICS- compared to ICS+ (mean total AQLQ score were 6.4 and 5.7 respectively, p<0.0001), reflecting a milder 
disease among individuals not using ICS. Nevertheless, the multivariate analysis stratified on ICS use over the 
past 12 months showed that in both groups and for all domains, except for Activity Limitation in ICS-, 
uncontrolled asthma was related to significant decreased scores of at least 0.5 point compared to controlled 
asthma (table 2).   
The physical and mental summary component scores and all SF-36 domains were significantly decreased in 
uncontrolled asthma compared to controlled asthma (Table 3). For three domains, Role Physical, General Health 
and Role Emotional, the score differences were stronger than the MCID thresholds defined for asthma (13.2, 
12.6 and 16.7 respectively). Compared to controlled asthma, partly-controlled asthma was associated with a 
significantly lower PCS score, but no association was observed with the MCS score (table 3). Partly-controlled 
asthma showed similar SF-36 scores to controlled asthma for all domains, except for the General Health domain 
where a statistically significant difference was observed but the difference (6.4) was lower than the MCID 
previously proposed in asthma for this domain.  
Generic quality of life (SF-36) in individuals with controlled asthma vs individuals without asthma 
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Mean SF-36 physical and mental summary scores were lower in the whole group of individuals with asthma as 
compared to individuals without asthma (adjusted means (SE) in individuals with asthma and individuals 
without asthma were for the PCS score 51.8 (0.45) vs 54.1 (0.31), p<0.0001 and for the MCS score 46.5 (0.65) 
vs 49.2 (0.56), p=0.0007).  
Individuals with controlled asthma had similar PCS scores and lower MCS scores when compared to those 
without asthma (table 3). Similar results were observed even in subjects with controlled asthma who had used 
ICS in the past year (n=54) (adjusted mean (SE) PCS scores were 53.9 (0.8) and 54.3(0.4) and adjusted mean 
(SE) MCS score were 47.7 (1.4) and 49.2 (0.6) for controlled asthma and non asthma respectively). Regarding 
each SF-36 domain, individuals with controlled asthma showed statistically significantly lower scores for 
Physical Functioning, General Health, Social Functioning and Mental Health compared to individuals without 
asthma. However none of the observed differences reached 5 when the MCIDs defined in asthma for these 
domains are 10 or greater, indicating that although being statistically significant, the magnitudes of the 
differences were relatively small.  
DISCUSSION  
Uncontrolled asthma, assessed by combining epidemiological data on day and night symptoms, use of reliever 
therapy, lung function and exacerbation was significantly associated with a decreased HRQL, with differences 
compared to controlled asthmatics that exceeded the MCID. This study, by comparing HRQL between subjects 
with controlled asthma and healthy subjects, suggests that the health status impairment is minimal if asthma 
control is achieved.  
The strength of the present analysis lies on the large and well characterized population of adults with asthma and 
without asthma recruited in the framework of the EGEA study. In the present analysis, a sensitive current asthma 
phenotype, supported by the high frequencies of the allergic phenotypes and of BHR among the individuals with 
asthma, and a specific definition of individuals without asthma were used. Another strength of the present 
analysis is the use of both a standardized generic questionnaire (SF-36) and an asthma specific questionnaire 
(AQLQ). Data available in the EGEA2 study made it possible to take into account a large number of 
confounders 3. The comprehensive asthma control classification used allows accounting for multiple features of 
asthma control by combining both objective and subjective measures of asthma control. The inclusion of lung 
function in the asthma control assessment is supported by a previous factorial analysis showing that asthma 
health status is composed of distinct components, lung function being one of them 25, and by clustering analysis 
showing that an impaired lung function is observed for specific asthma phenotypes 26 .   However, a limitation of 
this classification lies on the lack of data on activity limitation, one dimension of asthma control integrated in the 
GINA guidelines. Nevertheless, the lack of this dimension is expected to impair asthma control classification in 
only few subjects, as suggested by unpublished data in ECRHSII showing that among1032 patients with current 
asthma the activity limitation had an impact on the asthma control level in only 8.7% subjects. Compared to the 
time period used in some asthma control questionnaires or following the current clinical guidelines (one to four 
weeks), a longer time period was used in the EGEA study (3 months), which most likely results in decreasing the 
strength of the association with HRQL, as HRQL questionnaire relates to a much shorter time (2 weeks for the 
AQLQ and 4 weeks for the SF-36 questionnaire). However, there is no reason to expect a differential or 
systematic bias that would lead to underestimate or overestimate the association. The lack of asthma control in 
this population is due either to under-treatment (supported by the observation that 42% and 30% of the 
individuals with partly-controlled and uncontrolled asthma respectively did not use ICS in the past year) or to the 
lack of response to asthma treatment (supported by the observation that half of the subjects with uncontrolled 
asthma used high daily treatment level, GINA step 3 and 4, in the past 3 months) as previously reported3.   
Present findings show that uncontrolled asthma was significantly associated with decreased AQLQ scores, which 
confirm previous studies using standardized asthma control tools 4, 5.   Individuals with partly-controlled asthma 
had intermediate AQLQ scores between those with controlled and uncontrolled asthma. Our results, showing a 
greater impact of partly-controlled asthma on the symptoms domain compared to the emotional function and 
environmental exposure domains are in agreement with previous studies 19, 27.  The lack of  difference between 
partly controlled asthma and controlled asthma using the SF-36 questionnaire, may be explained by a lower 
sensitivity of generic questionnaires to detect small differences in HRQL 28. 
Clinical and epidemiological studies have shown a decreased HRQL in more severe asthma 29-31. The similar 
pattern of association between asthma control and AQLQ score observed among subjects using ICS treatment 
and those not using ICS treatment suggests that the proposed asthma control classification is able to discriminate 
levels of HRQL in both individuals with mild and more severe asthma.   
As expected and previously shown in other populations, individuals with asthma as a group had an impaired 
quality of life compared to individuals without asthma 9, 10. Moreover, our results indicate that HRQL in 
individuals with controlled asthma is comparable to HRQL in individuals without asthma. The lack of 
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association between the SF-36 PCS score and controlled asthma is not due to a lack of statistical power as the 
power of 80% was reached for differences between control asthma and no asthma greater than 1.3; this 
represents a really reasonable difference compared with previous published articles in population-based study 
showing PCS decreased by 5 points with asthma 10. The lack of difference between SF-36 component summary 
scores and controlled asthma was observed for the group of individuals with asthma who had used ICS in the 
past year and it may be an important message for encouraging the achievement of optimal control in populations. 
It is unlikely that potential misclassification could explain this result since asthma characterization was good. 
Although no major differences between individuals with asthma and those without asthma was observed on 
several personal and socio-economic characteristics (sex, smoking, educational level and BMI), selection bias 
may have occurred on other factors and a replication of our results in a larger population-based study is 
warranted.  
Conclusion 
The proposed approach to assess asthma control in epidemiology, using a comprehensive manner adapted from 
the GINA guidelines, is strongly associated with HRQL. Furthermore, although some of the SF-36 domain 
scores differences were statistically different between individuals with controlled asthma and those without 
asthma, the differences observed were of small magnitude, indicating that the health status impairment is 
minimal if asthma control is achieved. These results support the discriminative properties of such an asthma 
control grading system applicable in epidemiological studies. Its use in epidemiology could provide useful tools 
to identify risk factors for uncontrolled asthma and to compare the quality of asthma management between 
different populations.  
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Figure 1: Flowchart of the EGEA population 
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Table 1. Characteristics of the population   
 Individuals without  Individuals with asthma 
 asthma and co-morbidity* 
n= 584 
All 
n= 498 
Controlled 
n=221 
Partly controlled 
n=148 
Uncontrolled 
n=129 
Age,  m ± sd (n) 43.8 ± 15.6 (584) 39.4 ±16.4 (498) § 36.8±15.5 (221) 40.6±17.0 (148) 42.4±16.6 (129) 
Sex, % males (n) 46.7 (273) 50.8 (253) 53.8 (119) 54.7 (81) 41.1 (53) 
Educational level 
University, % (n) 
Secondary, % (n) 
Primary, % (n) 
 
51.1 (297) 
25.5 (148) 
23.4 (136) 
 
49.3 (241) 
29.0 (142) 
21.7 (106) 
 
49.3 (109) 
31.2 (69) 
19.5 (43) 
 
53.1 (77) 
24.1 (35) 
22.8 (33) 
 
44.7 (55) 
30.9 (38) 
24.4 (30) 
Current active/passive smoking  
Non/ex smokers and ETS†-, % (n) 
Non/ex smokers and ETS†+, % (n) 
Current smokers, % (n) 
 
39.0 (226) 
39.4 (228) 
21.6 (125) 
 
34.2 (170) 
40.2 (200) 
25.6 (127) 
 
33.0 (73) 
38.5 (85) 
28.5 (63) 
 
33.8 (50) 
45.3 (67) 
20.9 (31) 
 
36.7 (47) 
37.5 (48) 
25.8 (33) 
BMI ≥ 25 kg/m2, % (n) 35.7 (199) 36.7 (178) 33.9 (75) 37.1 (53) 41.3 (50) 
Co-morbidity*, % (n) -- 19.3 (96) 16.7 (37) 20.3 (30) 22.5 (29) 
Sensitization, %  (n) 40.1 (210) 81.1 (369) § 79.5 (167) 81.5 (110) 83.6 (92) 
Active rhinitis, %  (n) 18.9 (109) 60.8 (298) § 56.6 (124) 60.8 (87) 68.0 (87) 
Total IgE ≥100 IU/ml, %  (n) 29.2 (162) 61.5 (297) § 54.1 (118) 68.5 (98) 66.4 (81) 
BHR, PD20≤4mg, % (n) 26.3 (103) 70.5 (198) § 66.7 (110) 74.6 (50) 77.5 (38) 
Asthma      
Status in the study:  Case, % (n) 
       Relatives or controls, % (n) 
 50.2 (250) 
49.8 (248) 
37.2 (93) 
51.6 (128)  
30.8 (77) 
28.6 (71) 
32.0 (80) 
19.8 (49) 
Asthma onset: ≤4 years, % (n) 
                 ]4-16] , % (n) 
                       > 16, % (n) 
-- 
-- 
-- 
31.1 (146) 
34.5 (162) 
34.3 (161) 
31.5 (65) 
38.4 (79) 
30.1 (62) 
30.3 (43) 
33.1 (47) 
36.6 (52) 
31.4 (38) 
29.7 (36) 
38.8 (47) 
ICS use in the past 12 months % (n) -- 49.4 (244) 31.0 (68) 58.2 (85) 70.5 (91) 
*  Non-expected co-morbidity was assessed by a positive answer to “Have you ever been treated or followed for rheumatism, Crohn disease, poly-arthritis, heart disease, 
diabetes, or other serious illnesses”. For individuals who answered “other serious illnesses”, the specific disease was reported and a medical doctor decided whether the 
condition(s) declared could be considered as a co-morbid condition in the context of this study of HRQL. † ETS : Environmental Tobacco Smoke. § p<0.001 for the 
difference between individuals without asthma those with asthma 
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Table 2. Disease-specific quality of life (AQLQ) according to asthma control 
 Adjusted* mean (SE) AQLQ scores 
 Activity 
Limitation 
Symptoms Emotional 
Function 
Environmental 
Exposure 
AQLQ total 
Among all individuals with asthma (n=429)     
 Controlled asthma (ref.) 6.3 (0.06) 6.3 (0.07) 6.5 (0.08) 6.4 (0.09) 6.4 (0.06) 
 Partly-controlled asthma 6.0 (0.09) § 5.7 (0.10) § 6.1 (0.12) § 6.0 (0.11) § 5.9 (0.08) § 
 Uncontrolled asthma 5.7 (0.11) § 5.1 (0.12) § 5.7 (0.13) § 5.6 (0.12) § 5.4 (0.10) § 
Among individuals with asthma who used ICS in the past 12 months (n=213) 
Controlled asthma (ref.) 6.3 (0.12) 6.1 (0.12) 6.4 (0.14) 6.2 (0.16) 6.2 (0.11) 
Partly-controlled asthma 6.0 (0.12) † 5.7 (0.13) † 6.1 (0.15) 6.0 (0.14) 5.9 (0.11) † 
Uncontrolled asthma 5.5 (0.14) § 4.9 (0.15) § 5.5 (0.16) § 5.5 (0.15) ‡ 5.3 (0.13) § 
Among individuals with asthma who did not used ICS in the past 12 months (n=212) 
Controlled asthma (ref.) 6.4 (0.08) 6.4 (0.08) 6.7 (0.08) 6.5 (0.12) 6.5 (0.07) 
Partly-controlled asthma 6.3 (0.12) 5.8 (0.13) § 6.2 (0.15) § 6.1 (0.18) † 6.1 (0.11) § 
Uncontrolled asthma 6.1 (0.13) † 5.7 (0.17) § 6.2 (0.17) ‡ 5.8 (0.22) ‡ 5.9 (0.13) § 
* Models were adjusted by age, sex, educational level, smoking, BMI, sensitization, allergic rhinitis, IgE, co-morbidity and centre 
† p < 0.05; ‡ p < 0.01; § p < 0.001 in comparison with the reference group (controlled asthma) and estimated with mixed model with a robust estimate of the standard errors 
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Table 3. Generic quality of life (SF36) according to asthma and asthma control  
 Adjusted* mean (SE) SF-36 physical component scores  Adjusted* mean (SE) SF-36 mental component scores 
 Physical 
Functioning 
Role  
Physical 
Bodily  
Pain 
General 
Health 
PCS  Vitality Social 
Functioning 
Role 
Emotional 
Mental 
Health 
MCS 
No asthma 93.1 (0.7) 91.3 (1.4) 78.3 (1.2) 75.3 (0.9) 54.1 (0.4)  60.3 (1.0) 84.8 (1.2) 84.5 (1.7) 68.9 (0.9) 49.0 (0.5) 
Controlled asthma 89.4 (1.1) 88.3 (2.0) 78.9 (1.7) 70.2 (1.3) 53.1 (0.5)  58.0 (1.3) 79.7 (1.6) 80.5 (2.4) 65.5 (1.5) 47.4 (0.9) 
Partly-controlled asthma 87.6 (1.3) 88.6 (2.5) 78.6 (2.3) 63.8 (1.9) 51.7 (0.7)  56.9 (1.6) 77.9 (2.0) 83.3 (3.1) 65.9 (1.6) 47.8 (0.9) 
Uncontrolled asthma 82.8 (1.7) 75.1 (3.6) 70.6 (2.4) 57.6 (1.9) 49.2 (0.9)  51.7 (2.0) 68.8 (2.6) 63.8 (4.3) 60.2 (2.1) 43.1 (1.4) 
 
Statistical test for the comparison of HRQL scores between controlled asthma and no asthma 
Controlled asthma vs. no 
asthma,  
     Scores difference 
     p value 
 
 
-3.7 
0.002 
 
 
-3.0 
0.19 
 
 
0.6 
0.79 
 
 
-5.1 
0.0004 
 
 
-1 
0.09 
 
 
 
-2.3 
0.14 
 
 
-5.1 
0.005 
 
 
-4.0 
0.14 
 
 
-3.4 
0.03 
 
 
-1.6 
0.05 
            
Statistical test for the comparison of HRQL scores between asthma control steps 
Partly-controlled vs. controlled 
asthma 
     Scores difference 
     p value 
 
 
-1.8 
0.25 
 
 
0.3 
0.90 
 
 
-0.3 
0.91 
 
 
-6.4 
0.002 
 
 
-1.4 
0.05 
  
 
-1.1 
0.55 
 
 
-1.8 
0.42 
 
 
2.8 
0.43 
 
 
0.4 
0.82 
 
 
0.4 
0.74 
Uncontrolled vs. partly-controlled 
asthma  
     Scores difference 
     p value 
 
 
-4.8 
0.02 
 
 
-13.5 
0.001 
 
 
-8.0 
0.01 
 
 
-6.2 
0.02 
 
 
-2.5 
0.02 
  
 
-5.2 
0.03 
 
 
-9.1 
0.004 
 
 
-19.5 
0.0002 
 
 
-5.7 
0.03 
 
 
-4.7 
0.005 
Uncontrolled vs. controlled 
asthma 
     Scores difference 
     p value  
 
 
-6.6 
0.0006 
 
 
-13.2 
0.0006 
 
 
-8.3 
0.004 
 
 
-12.6 
<0.0001 
 
 
-3.9 
<0.0001 
  
 
-6.3 
0.008 
 
 
-10.9 
0.0002 
 
 
-16.7 
0.0006 
 
 
-5.3 
0.03 
 
 
-4.3 
0.008 
 
* Models were adjusted by age, sex, educational level, smoking, BMI, sensitization, allergic rhinitis, IgE and centre 
Adjusted means were estimated with mixed model with a robust estimate of the standard errors 
 
